Real-time measurement of non-lethal platelet thromboembolic responses in the anaesthetized mouse

Summary

Identifying and evaluating new therapeutic targets in platelets requires advanced animal models in which platelet responses can be measured directly and in situ.This is important because platelet function is strongly influenced by external factors such as those originating from the vascular endothelium. Our objectives were to record graded, non-lethal thromboembolic platelet responses to platelet agonists in situ in the mouse and to demonstrate an inhibitory effect of aspirin in our model. Radiolabelled platelets were infused into anaesthetized mice and responses to ADP, collagen and thrombin measured as changes in platelet associated counts in miniaturized detection probes placed over the thoracic region. All agonists induced dose-dependent changes in platelet counts due to accumulation of thrombi in the pulmonary vasculature. We confirmed a specific platelet effect by comparing platelet and erythrocyte responses and showing platelet aggregates in the lung vasculature histologically. Simultaneous injection of collagen and adrenaline induced increased and protracted synergistic platelet responses compared with individual injection of these agents and aspirin inhibited collagen-induced responses. We confirmed the clinical relevance of our model by showing that platelet thromboembolism in the mouse, like pulmonary embolism in humans, impaired cardiovascular performance. We present a refined method for measuring platelet agonist dose-responses and thromboembolism in real-time without inducing mortality in the mouse. Our technique will be useful in investigating the molecular determinants of physiological and pathophysiological platelet function in an in-vivo context and will enable investigations of both platelet and non-platelets mediators of thrombus formation.

Keywords

Animal model - platelet - mouse - thrombosis

• References

• 1 Morley J, Page CP. Platelet aggregometry in vivo. Trends in Phal Sci 1984; 5: 258-260.
• 2 Andrews DA, Low PS. Role of red blood cells in thrombosis. Curr Opin Hematol 1999; 6: 76-82.
• 3 Elstad MR, McIntyre TM, Prescott SM. et al. The interaction of leukocytes with platelets in blood coagulation. Curr Opin Hematol 1995; 2: 47-54.
• 4 Nieswandt B, Aktas B, Moers A. et al. Platelets in atherothrombosis: lessons from mouse models. J Thromb Haemost 2005; 3: 1725-1736.
• 5 Mitchell JA, Warner TD. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov 2006; 5: 75-86.
• 6 Okada K, Ueshima S, Matsuno H. et al. Effect of staphylokinase-derived nonadecapeptide on the activation of plasminogen. Thromb Haemost 2007; 97: 795-802.
• 7 DiMinno G, Silver MJ. Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol. J Pharmacol Exp Ther 1983; 225: 57-60.
• 8 Konstantinides S, Schafer K, Neels JG. et al. Inhibition of endogenous leptin protects mice from arterial and venous thrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 2196-2201.
• 9 Huang J, Wang S, Luo X. et al. Cinnamaldehyde reduction of platelet aggregation and thrombosis in rodents. Thromb Res 2007; 119: 337-342.
• 10 May GR, Herd CM, Butler KD. et al. Radioisotopic model for investigating thromboembolism in the rabbit. J Pharmacol Methods 1990; 1: 19-35.
• 11 Emerson M, Momi S, Paul W. et al. Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature. Thromb Haemost 1999; 81: 961-966.
• 12 Pitchford SC, Riffo-Vasquez Y, Sousa A. et al. Platelets are necessary for airway wall remodeling in a murine model of chronic allergic inflammation. Blood 2004; 103: 639-647.
• 13 Konstantinides S. Pulmonary embolism: impact of right ventricular dysfunction. Curr Opin Cardiol 2005; 20: 496-501.
• 14 Menys VC. Collagen induced human platelet aggregation: serotonin receptor antagonism retards aggregate growth in vitro. Cardiovasc Res 1993; 27: 1916-1919.
• 15 Huang EM, Detwiler TC. Characteristics of the synergistic actions of platelet agonists. Blood 1981; 57: 685-691.
• 16 Li N, Hu H, Hjemdahl P. Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. Thromb Res 2003; 111: 165-170.
• 17 Storey RF, Judge HM, Wilcox RG. et al. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost 2002; 88: 488-494.